1 week Ago By Defense World Staff
Research analysts at StockNews.com started coverage on shares of Akari Therapeutics ( NASDAQ:AKTX – Get Free Report ) in a report issued on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Akari Therapeutics Trading Up 8.3 % Shares of NASDAQ:AKTX opened at $1.31 on Friday.
The company has a 50 day moving average of $1.53 and a 200-day moving average of $2.66.
Akari Therapeutics has a one year low of $0.90 and a one year high of $4.40.
About Akari Therapeutics ( Get Free Report ) See Also Five stocks we like better than Akari Therapeutics Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time Quantum Opportunity: Skywater Technology’s Long-Term Potential Conference Calls and Individual Investors Nebius Group: The Rising Star in AI Infrastructure How to Use the MarketBeat Dividend Calculator MarketBeat Week in Review – 12/30 – 1/03 Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
